制瘤素M驱动肠道炎症并可预测炎症性肠病患者对肿瘤坏死因子中和治疗的应答
炎症性肠病(IBD)患者炎症肠组织中制瘤素M(OSM)及其受体(OSMR)表达升高,与组织病理学疾病严重程度密切相关;在抗TNF耐药动物模型中,敲除或阻断OSM可显著减轻结肠炎;对超过200例IBD患者(含英夫利西单抗和戈利木单抗两项3期试验队列)的分析显示,治疗前OSM高表达与抗TNF治疗失败强烈相关。
要点
- IBD炎症肠组织中OSM及OSMR表达升高,与组织病理学疾病严重程度密切相关。
- 抗TNF耐药动物模型中,敲除或药物阻断OSM可显著减轻结肠炎。
- 超过200例IBD患者中,治疗前OSM高表达与抗TNF治疗失败强烈相关。
核心结论
- OSM是IBD的潜在生物标志物和治疗靶点,尤其与抗TNF耐药患者相关。
研究设计与样本
- 研究比较IBD患者炎症肠组织与健康对照的OSM及OSMR表达,并在抗TNF耐药动物模型中评估遗传缺失或药物阻断OSM对结肠炎的影响。
- 分析纳入超过200例IBD患者,包括英夫利西单抗和戈利木单抗两项3期临床试验的两个队列。
主要发现
- 与健康对照相比,IBD患者炎症肠组织表达高水平OSM及其受体OSMR,且与组织病理学疾病严重程度密切相关。
- OSMR表达于非造血、非上皮的肠基质细胞,该细胞响应OSM产生IL-6、白细胞黏附因子ICAM1及招募中性粒细胞、单核细胞和T细胞的趋化因子等促炎分子。
- 在抗TNF耐药肠炎动物模型中,遗传缺失或药物阻断OSM显著减轻结肠炎。
- 超过200例IBD患者分析显示,治疗前OSM高表达与抗TNF治疗失败强烈相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are complex chronic inflammatory conditions of the gastrointestinal tract that are driven by perturbed cytokine pathways. Anti-tumor necrosis factor-α (TNF) antibodies are mainstay therapies for IBD. However, up to 40% of patients are nonresponsive to anti-TNF agents, which makes the identification of alternative therapeutic targets a priority. Here we show that, relative to healthy controls, inflamed intestinal tissues from patients with IBD express high amounts of the cytokine oncostatin M (OSM) and its receptor (OSMR), which correlate closely with histopathological disease severity. The OSMR is expressed in nonhematopoietic, nonepithelial intestinal stromal cells, which respond to OSM by producing various proinflammatory molecules, including interleukin (IL)-6, the leukocyte adhesion factor ICAM1, and chemokines that attract neutrophils, monocytes, and T cells. In an animal model of anti-TNF-resistant intestinal inflammation, genetic deletion or pharmacological blockade of OSM significantly attenuates colitis. Furthermore, according to an analysis of more than 200 patients with IBD, including two cohorts from phase 3 clinical trials of infliximab and golimumab, high pretreatment expression of OSM is strongly associated with failure of anti-TNF therapy. OSM is thus a potential biomarker and therapeutic target for IBD, and has particular relevance for anti-TNF-resistant patients.
引用
- West NR, Hegazy AN, Owens BMJ, et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med. 2017. PMID: 28368383. doi:10.1038/nm.4307
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。